NCT05688176Recruiting
Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers
Source: ClinicalTrials.gov · Last updated 17 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 12 Jul 2018
- Start date
- Jun 2016
- Primary completion date
- 31 Jan 2027
- Lead sponsor
- University Hospital, Ghent
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05688176
What you commit to
- Study type: Observational
- Planned participants: 100
- From Jun 2016 to the primary completion date, 31 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active bacterial, viral or fungal infection
- Parenchymal liver disease (any stage cirrhosis)
- High risk of bleeding during biopsy (anticoagulants, esophageal varices)
- Psychiatric pathology capable of affecting comprehension and judgement faculty
Other
- Pregnancy or breast feeding
- Esophageal squamous cell carcinoma
- Helicobacter pylori positive at the time of biopsy sampling
- Radiofrequency ablation of the oesophagus
Who the study is looking for
- Barrett's Esophagus with length \> 3cm OR esophageal adenocarcinoma histologically proven
- Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent
- Age over 18 years
- No other concurrent malignant disease
- No inclusion in other clinical trials interfering with the study protocol
- No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy
- Absence of any severe organ insufficiency
- No pregnancy or breast feeding
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Ghent Coordinator of this site? Confirm its status | Ghent | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.